Skip to content

Use of Shenhuang Paste on Shenque Point Improves Chemotherapy Induced Gastrointestinal Toxicity in breast Cancer: a Randomized Controlled Trial.

Use of Shenhuang Paste on Shenque Point Improves Chemotherapy Induced Gastrointestinal Toxicity in breast Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003442
Enrollment
Unknown
Registered
2020-07-01
Start date
2020-07-25
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Sponsors

Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 40-60 years, KPS score >= 60 points, WBC >= 4.0 * 10^9L-1 before treatment, normal liver and renal function, expected survival > 3 months; 2. All were pathologically confirmed breast cancer patients who met the CLINICAL practice guidelines for NCCN breast cancer (2018.v1) after modified radical mastectomy and received chemotherapy with AC regimen (adriamycin + cyclophosphamide) or TAC regimen (docetaxel + adriamycin + cyclophosphamide) for the first time. 3. It conforms to the provisions of "Standard of Curative Effect of Diagnosis of Diseases and Syndromes of Traditional Chinese Medicine" and "Guiding Principles for Clinical Research of New Chinese Medicines"; 4. All the selected patients have signed informed consent and are willing to accept the treatment of this program.

Exclusion criteria

Exclusion criteria: 1. Other complications and liver and kidney dysfunction; 2. patients receiving other traditional Chinese medicine intervention (such as taking traditional Chinese medicine, traditional Chinese medicine application, etc.);

Design outcomes

Primary

MeasureTime frame
Condition of defecation;

Secondary

MeasureTime frame
Analysis of fecal flora and metabolites;hemanalysis;

Countries

China

Contacts

Public ContactXiaohong Xu

Zhejiang Chinese Medical Universtiy

330272940@qq.com+86 18767167250

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026